Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $422K | $10.5M | $0.00 | $10.4M | $353K | $235K | $190K |
| Revenue growth | — | — | — | — | 2377.5% | -100.0% | — | -96.6% | -33.4% | -19.1% |
| Operating income | -$57.9M | -$47.1M | -$32.8M | -$23.0M | -$15.9M | -$34.0M | -$46.4M | -$54.9M | -$67.9M | -$77.6M |
| Operating margin | — | — | — | -5445.0% | -152.2% | — | -446.8% | -15557.8% | -28899.6% | -40856.3% |
| Net income | -$57.9M | -$48.2M | -$34.5M | -$16.2M | -$16.2M | -$33.8M | -$45.3M | -$50.4M | -$64.0M | -$74.1M |
| Net margin | — | — | — | -3844.5% | -155.2% | — | -436.5% | -14274.5% | -27243.8% | -39009.5% |
| EPS (diluted) | -$2.44 | -$26.13 | -$16.11 | -$7.03 | -$1.77 | -$1.77 | -$1.60 | -$0.94 | -$0.86 | -$0.80 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$52.9M | -$42.4M | -$31.1M | -$20.0M | -$15.3M | -$33.1M | -$41.9M | -$33.2M | -$69.1M | -$62.0M |
| Capital expenditures | $600K | $1.31M | $594K | $79.0K | $202K | $192K | $1.64M | $4.21M | $65.0K | $77.0K |
| Free cash flow | -$53.5M | -$43.7M | -$31.7M | -$20.1M | -$15.5M | -$33.3M | -$43.5M | -$37.4M | -$69.2M | -$62.1M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $38.4M | $21.1M | $23.0M | $9.21M | $17.0M | $2.34M | $9.98M | $22.5M | $11.1M | $10.7M |
| Total assets | $80.5M | $89.4M | $52.7M | $36.2M | $38.7M | $116M | $95.8M | $121M | $96.8M | $93.0M |
| Long-term debt | $9.20M | $14.7M | $8.26M | — | — | — | — | — | — | — |
| Shareholders' equity | $62.8M | $64.2M | $33.6M | $21.2M | $31.6M | $109M | $71.5M | $90.7M | $70.0M | $67.5M |
| Retained earnings | -$216M | -$264M | -$299M | -$322M | -$339M | -$372M | -$418M | -$468M | -$532M | -$606M |
| Shares (wtd avg diluted) | 23.7M | 29.8M | 2.19M | 3.89M | 9.16M | 19.1M | 28.4M | 53.6M | 74.3M | 93.0M |
Every figure is extracted from aTYR PHARMA INC’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.